Research ArticleCancer

PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity

See allHide authors and affiliations

Science Translational Medicine  08 Jul 2020:
Vol. 12, Issue 551, eaaz5683
DOI: 10.1126/scitranslmed.aaz5683

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

A helping hand for checkpoint blockade

Although immunotherapy using immune checkpoint blockade can be very effective against tumors such as melanoma, it does not work for all patients, and additional interventions continue to be necessary. Kim et al. found that the epigenetic modifier protein arginine methyltransferase 5 (PRMT5), which has multiple protumorigenic functions, promotes immunosuppression in melanoma by two different mechanisms. The authors delineated these immune mechanisms and demonstrated that inhibition of PRMT5 enhances the efficacy of immune checkpoint inhibition in multiple mouse models of melanoma, suggesting the combination’s potential for clinical translation.

View Full Text

Stay Connected to Science Translational Medicine